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Abstract 
Background 
There is increasing evidence that the Brugada ECG pattern is a marker of subtle 
structural heart disease.  
Objective 
We characterised Brugada syndrome (BrS) patients using cardiovascular magnetic 
resonance (CMR) with late gadolinium enhancement (LGE). 
Methods 
BrS was diagnosed according to international guidelines. 26% BrS patients carried 
SCN5A mutations. CMR data from 78 BrS patients were compared with 78 healthy 
controls (4415 vs 4214 years; p=0.434 and 64% vs 64% male; p=1.000). 
Results 
Right ventricular (RV) ejection fraction was slightly lower (61±8% vs 64±5%; p=0.004) 
and RV end-systolic volume slightly greater (31±10mL/m2 vs 28±6mL/m2; p=0.038) in BrS 
compared with controls. These values remained within the normal range. LGE was 
demonstrated in 8% BrS patients (left ventricular (LV) midwall LGE in 5%) but not in 
controls (p=0.028). In BrS patients with midwall LGE there were no other features of 
cardiomyopathy at the time of CMR but genetic testing and follow-up has revealed a 
desmoplakin mutation in one patient and evolution of T-wave inversion throughout all 
precordial ECG leads in another. Neither patient fulfils diagnostic criteria for 
arrhythmogenic right ventricular cardiomyopathy. 
Conclusion 
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Some BrS patients have LV midwall LGE consistent with an underlying cardiomyopathic 
process. Even cases without LGE show greater RV volumes and reduced RV function. 
These findings lend further support to the presence of subtle structural abnormalities in 
BrS. The BrS pattern with LGE may serve as early markers for evolution of a 
cardiomyopathic phenotype over time. CMR is a potentially useful adjunct investigation 
in the clinical evaluation of BrS. 
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Introduction 
The Brugada syndrome (BrS) is an inherited arrhythmia syndrome characterised by ST-
segment elevation in the right precordial ECG leads. It is associated with ventricular 
fibrillation (VF) and sudden cardiac death (SCD) in the absence of overt structural heart 
disease.(1)  
 
There is, however, increasing evidence to suggest that the Brugada ECG pattern is a 
marker of subtle cardiac structural abnormalities. Histopathological analysis of sudden 
death victims with prior electrocardiograms (ECG) suggestive of BrS has demonstrated 
right ventricular (RV) fibro-fatty infiltration similar to arrhythmogenic right ventricular 
cardiomyopathy (ARVC).(2) In some BrS patients, abnormalities including conduction 
delay and QRS fragmentation have been seen during electrophysiological studies. 
Combined the impression is of an overlap with subtle cardiomyopathy.(2–12)  
 
Data from cardiac imaging is sparse. Cardiovascular magnetic resonance (CMR) studies 
have produced conflicting results with some showing increased cardiac dimensions and 
reduced ventricular function in BrS patients compared with controls and others showing 
no apparent difference.(13–16) It appears that BrS patients carrying SCN5A mutations 
have greater ventricular volumes and lower ejection fractions compared with mutation 
negative BrS patients and healthy subjects.(16,17) In non-ischemic cardiomyopathies 
including dilated cardiomyopathy and hypertrophic cardiomyopathy, arrhythmogenesis 
has been associated with presence of late gadolinium enhancement (LGE) representing 
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focal myocardial fibrosis on CMR.(18,19) Systematic assessment for myocardial fibrosis 
in BrS has not been performed and therefore we sought to characterise a cohort of 
patients using the CMR LGE technique. 
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Methods 
Patient characteristics 
Patients with Brugada syndrome (BrS) were identified from a database at St George’s 
Hospital, London. All fulfilled international diagnostic criteria with: a type 1 BrS ECG 
pattern demonstrated in 1 ECG lead (V1-V3) in the 2
nd, 3rd or 4th intercostal space in the 
presence or absence of a sodium channel blocking agent.(20) These patients were under 
follow-up in the inherited heart disease clinic and had conventional investigation 
according to a standard diagnostic algorithm including 15 lead ECG, signal averaged ECG 
(SAECG), echocardiography, exercise testing, 12 lead Holter monitoring and ajmaline 
provocation testing.(21) Patients were considered symptomatic if there was a history of 
cardiac arrest or unexplained syncope with a negative tilt test result. A family history of 
sudden cardiac death was recorded if sudden death had occurred in a first degree 
relative <45 years old.(22) A spontaneous type 1 ECG pattern was recorded when the 
type 1 ECG pattern was seen in the absence of a sodium channel blocker. The SAECG 
was considered abnormal for late potentials when ≥2 of the following were 
demonstrated: filtered QRS duration ≥114ms; duration of the terminal QRS <40µV 
≥38ms; and root mean square voltage of the terminal 40ms ≤20µV. Genotyping for 
sodium channel mutations (SCN5A) was performed as part of routine clinical care.  
 
Healthy controls of a similar age and sex were identified from research databases. These 
were individuals without known cardiac risk factors, prior history of cardiac disease or 
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family history of inherited heart disease. The study was approved by the Local Research 
Ethics Committee. 
 
Cardiovascular magnetic resonance analysis 
Since 2010 patients diagnosed with BrS at St George’s Hospital have had CMR as part of 
the investigative algorithm. All BrS patients with complete CMR datasets were included 
in the study. There were 7 patient exclusions (2 had incomplete scans due to 
claustrophobia and 5 were not given gadolinium). The final population comprised 78 BrS 
patients (4415 years; 64% male). These were compared with 78 healthy controls 
(4214 years; 64% male). CMR scans were performed at St George’s Hospital and Royal 
Brompton Hospital, London, according to a standard protocol.(23) Cine images were 
performed using a steady state free precession sequence in three long axis and 
continuous short axis views covering the entire left ventricle (LV) and RV from base to 
apex. The LGE images were obtained in the same views using an inversion recovery 
sequence 10 minutes following administration of gadolinium (0.1mmol/kg). Studies 
were performed at 1.5 Tesla (Siemens Avanto; 40%) and 3.0 Tesla (Philips Achieva; 60%) 
field strength. Raw DICOM CMR data was obtained and de novo analysis was performed 
using dedicated software with valve plane tracking (CMR-tools 2012, Cardiovascular 
Imaging Solutions, London, UK). Measurements were made according to international 
guidelines (atrial areas from the horizontal long axis view, ventricular volumes including 
papillary muscles as myocardium from the short axis stack). (24) Atrial areas, ventricular 
volumes and mass were indexed to body surface area. Presence or absence of LGE was 
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recorded independently by two operators (AC and RB) and patterns of LGE were 
described. When there was disagreement the images were reviewed by a third operator 
(LA) and a consensus was reached. The presence of CMR fat infiltration within the 
myocardium was not specifically assessed or recorded as its identification has been 
shown to be of limited value in ARVC and was therefore less likely to be of utility in 
BrS.(25)  
 
Statistical analysis 
Statistical analyses were performed using IBM SPSS Statistics 22 (SPSS Inc., Chicago, 
Illinois, USA). Continuous variables are expressed as means ± standard deviation and 
categorical variables as percentages. Continuous variables were tested for normality 
using the Shapiro-Wilk test. Comparisons between groups were carried out using an 
unpaired t-test after controlling for equality of variances with the Levene’s test, Kruskal 
Wallis test or chi squared/Fisher’s exact test where appropriate. A two-tailed p value 
<0.05 was considered significant.  
11 
 
Results 
Patient characteristics 
BrS patients and healthy controls were similar in age (44±15 years vs 42±14 years; 
p=0.434) and gender (males 64% vs 64%; p=1.000). Their clinical characteristics are 
shown in table 1. 
 
Cardiovascular magnetic resonance analysis 
Brugada syndrome patients and normal controls 
Right ventricular ejection fraction (RVEF) was lower (61±8% vs 64±5%; p=0.004) and RV 
end systolic volume (RVESV) was greater (31±10mL/m2 vs 28±6mL/m2; p=0.038) in BrS 
patients compared with healthy controls. There were no significant differences in other 
size or function measurements between cohorts. Overall LGE was demonstrated in 6 
(8%) BrS patients (45±15 years; 83% male) and no healthy controls (table 2). LGE was 
found in patients studied at both 1.5T and 3.0T field strengths. Following exclusion of 
patients with LGE, RVEF remained lower (61±8% vs 64±5%; p=0.008) and RVESV greater 
(31±10mL/m2 vs 28±6mL/m2; p=0.026) in BrS patients compared with controls.  
 
Brugada syndrome patients with and without SCN5A mutations 
Right atrial (RA) area (12±2cm2/m2 vs 10±2cm2/m2; p=0.010), RV end diastolic volume 
(RVEDV) (78±18mL/m2 vs 74±12mL/m2; p=0.038), LV end diastolic volume (LVEDV) 
(74±14mL/m2 vs 71±11mL/m2; p=0.019) and LV end systolic volume (LVESV) 
(27±6mL/m2 vs 24±6mL/m2; p=0.024) were greater in patients with SCN5A mutations 
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compared to those without. Overall there was a trend towards greater cardiac 
dimensions and lower ventricular function in patients with SCN5A mutations, although 
this did not reach statistical significance across all variables (table 3). 
 
Patterns of late gadolinium enhancement in Brugada syndrome 
Where LGE was present in patients with BrS, it was found most frequently in the LV 
midwall (4 patients; 5%). The distribution was varied and included septal and 
inferolateral locations as well as multiple locations within one patient (figure 1 and table 
4). LGE was also found at the RV insertion points but was not seen in the RV 
myocardium.  
 
Clinical characteristics of patients with LV midwall late gadolinium enhancement 
There were four patients with midwall LV LGE (figure 1 and table 4). All were 
asymptomatic. Patients 1 and 2 were siblings with ajmaline induced type 1 ECG pattern 
and a family history of sudden cardiac death (SCD) during sleep (son of patient 1). 
Patient 3 had ajmaline induced type 1 ECG pattern with a family history of SCD at rest 
(sister). Patient 4 had a spontaneous type 1 ECG pattern with a family history of SCD 
(uncle). At the time of CMR assessment patient 1 had T wave inversion in ECG leads V1 
and V2 but no other features of cardiomyopathy. All four patients had otherwise 
unremarkable ECGs and SAECGs, normal transthoracic echocardiograms and no 
significant arrhythmias on exercise testing or Holter monitoring. SCN5A mutation 
analysis was negative in patient 2 (therefore not repeated in her brother patient 1), 
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patient 3 and patient 4. In patient 3 further genetic testing has revealed a mutation in 
the desmoplakin gene. 
 
Follow-up  
Two patients (3%) were lost to follow-up but the remaining 76 patients have been 
followed up for 31±21 months. Two patients (3%), both of whom presented initially with 
VF cardiac arrest, had further VF events shocked appropriately by their implantable 
cardioverter-defibrillators. Two patients (3%) without prior arrhythmia developed non-
sustained ventricular tachycardia without haemodynamic compromise. Two patients 
(3%) developed sinus node disease and three patients (4%) developed atrial fibrillation. 
One further patient died secondary to septicaemia. None of these had LGE on their 
presenting CMR. Of the four patients (5%) with BrS and midwall LGE, followed for 45±15 
months, one developed T wave inversion across all precordial ECG leads after 25 months 
(patient 2; figures 2 and 3), but none suffered a SCD event, VF or any other arrhythmia. 
Follow-up for the remaining patients has been unremarkable. 
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Discussion 
This study demonstrated an increased prevalence of myocardial fibrosis in BrS patients 
compared with healthy controls. BrS patients with midwall LGE had strong family 
histories of sudden cardiac death but were asymptomatic and during a short follow-up 
presence of LGE did not appear to predict arrhythmic events. The presence of LGE was 
therefore not associated with arrhythmogenesis or a personal risk of sudden death.  
 
Previous CMR studies of BrS patients have not focused on LGE assessment. Analysis of a 
smaller cohort failed to demonstrate evidence of LGE.(15) Rudic et al. found LV 
subepicardial LGE in 1/60 BrS patients consistent with healed myocarditis and 
compatible with the patient’s past medical history.(16) Van Hoorn et al. found LGE in 
3/40 SCN5A mutation positive and 3/98 SCN5A mutation negative BrS patients but the 
location, pattern and relevance of LGE was not specified.(17) 
 
Our data demonstrated mildly reduced RV systolic function (RVEF) and mildly increased 
RV systolic volume (RVESV) in BrS patients compared with controls. However these 
values remained within the normal range. These findings are similar to other CMR 
studies in BrS where lower RVEF and increased RVESV as well as greater RV outflow 
tract dimensions have been reported.(13,14,16) There are minor differences in absolute 
values for volumes and function between studies which likely reflect use of different 
software analysis programs and methods for tracing the endocardial borders (including 
or excluding papillary muscle mass) but results of the comparisons are similar.  
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From previous data it appears that increased atrial and ventricular dimensions and 
reduced ventricular function in BrS may be driven by patients with SCN5A 
mutations.(16,17) There were greater cardiac dimensions and reduced ventricular 
function in our SCN5A mutation positive BrS patients compared with their mutation 
negative counterparts. However this difference was not significant for all variables 
which likely reflects the smaller number of patients carrying an SCN5A mutation in this 
cohort.  
 
Clinical implications in patients with BrS 
RV insertion point LGE is found in patients with hypertrophic cardiomyopathy but may 
also be found in normal individuals and is of unclear clinical significance.(26) Midwall 
LGE is associated with pathology. In our BrS patients midwall LGE was similar to that 
seen in non-ischemic cardiomyopathies and myocarditis.(27) These patients were 
diagnosed with BrS based on current guidelines.(20) All of the patients with midwall LGE 
therefore fulfilled diagnostic criteria for BrS and during comprehensive clinical 
evaluation none of these patients demonstrated a cardiomyopathy phenotype at the 
time of CMR. There was T wave inversion in ECG leads V1 and V2 in one patient but 
otherwise all four patients had unremarkable ECGs and SAECGs, normal transthoracic 
echocardiograms and no significant arrhythmias on exercise testing or Holter 
monitoring. This is potentially important as current practice does not include CMR in the 
routine clinical evaluation of BrS, particularly if the echocardiogram is normal and the 
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ECG does not suggest structural abnormalities.(20,21) Underlying cardiomyopathy may 
therefore be missed. During subsequent short follow-up the ECG in one patient has 
evolved to demonstrate T wave inversion across all precordial leads and further genetic 
testing in another patient revealed a desmoplakin mutation. Both of these are major 
criteria for ARVC, but these patients exhibit no other Task Force features of this 
condition and as yet neither fulfils diagnostic criteria for definite ARVC.(28)  
 
Repolarization abnormalities vs conduction slowing in BrS 
There are two competing hypotheses for the mechanism of ST-segment elevation and 
ventricular arrhythmia in BrS: the repolarization and the conduction slowing theories. 
The repolarization theory suggests that unopposed action of the Ito current in RV 
epicardium leads to dispersion of repolarization allowing re-entry and initiation of 
arrhythmia. The conduction slowing theory suggests that delayed conduction in the 
RVOT facilitates re-entry and subsequent arrhythmia. Although the repolarization 
theory has received most support from the scientific community, there is increasing 
evidence to suggest that the BrS ECG pattern is a marker of subtle structural heart 
disease.(2–12) It appears that BrS requires subtle structural abnormalities with sodium 
channel dysfunction, and the role of SCN5A mutations is likely modulatory. (29) 
 
Prior to the original description of BrS, a case series of patients with idiopathic VF and 
right precordial ST-segment elevation documented RV structural abnormalities.(30) 
Subsequent histopathological studies in sudden death cases with prior ECGs suggestive 
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of BrS have demonstrated evidence of fibro-fatty infiltration in the RV. This suggested 
an overlap of BrS with ARVC.(2) Our group previously used histopathological 
morphometric quantification of collagen and connexin 43 (Cx43) and identified a higher 
collagen and lower Cx43 content in the RVOT of sudden arrhythmic death syndrome 
(SADS) cases with an associated familial diagnosis of BrS compared with controls.(3) This 
was correlated with in vivo evidence of conduction delay. In addition, endomyocardial 
biopsies from living patients with BrS have demonstrated a variety of structural changes 
including lymphocytic myocarditis, myocyte hypertrophy, mild fibrosis and fatty 
infiltration.(4,5) 
 
Left ventricular midwall LGE in BrS 
BrS is usually regarded as a disease of the RV and RVOT, but here fibrosis was 
demonstrated within the LV myocardium. This is in keeping with histopathology from 
SADS/BrS cases where higher collagen content was demonstrated in LV as well as RV 
myocardium.(3) The lack of RV LGE on CMR may reflect the difficulties associated with 
imaging the thin walled RV myocardium using current clinical techniques, as opposed to 
excluding the presence of fibrosis.(25) We agree with others who have hypothesized 
that RV fibrosis, undetectable using current imaging technology, is also present in these 
patients and explains the BrS ECG phenotype.(11,12,29) Our data therefore lend 
support to the depolarization hypothesis and the presence of subtle structural 
abnormalities in patients with BrS.  
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It is possible that the LV midwall LGE in these patients reflects healed myocarditis 
although there was nothing in their medical histories to suggest this. Similar patterns of 
LGE found in two siblings make a genetic cause more likely. This suggests a degree of 
phenotypic overlap between BrS and inherited cardiomyopathies and LGE may serve as 
an early marker for evolution of a subtle but more clinically appreciable 
cardiomyopathic phenotype over time. When patients with LGE were excluded, BrS 
patients still exhibited mildly reduced RV systolic function (RVEF) and mildly increased 
RV systolic volumes (RVESV), and in these patients diffuse underlying fibrosis may 
therefore be more relevant. 
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Study Limitations 
This is a retrospective study which utilised two different MRI scanners. There were small 
numbers of BrS patients with LV LGE myocardial fibrosis. RV LGE was not seen, but given 
the inherent difficulties associated with CMR imaging of the thin walled RV myocardium, 
the absence of RV LGE does not exclude RV fibrosis. Overt structural abnormalities were 
not seen in the majority of BrS patients and subtle anomalies and diffuse fibrosis may be 
more relevant. LGE cannot image diffuse interstitial fibrosis and other CMR techniques 
(T1 mapping) may therefore be considered in future studies.(31) 
 
Conclusion  
Some BrS patients have left ventricular midwall LGE consistent with an underlying 
cardiomyopathic process. Even cases without LGE show greater RVESV and lower RVEF 
on average. These findings lend further support to the presence of subtle structural 
abnormalities in BrS and the depolarization hypothesis. LGE may serve as an early 
marker for evolution of a cardiomyopathic phenotype over time. CMR is a potentially 
useful adjunct investigation in the clinical evaluation of BrS. 
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Figures 
Figure 1 Cardiovascular magnetic resonance imaging in Brugada syndrome (BrS). The left 
sided panel demonstrates extensive late gadolinium enhancement (LGE) in a 45 year old 
male patient (patient 1) with BrS. Patchy midwall LGE is demonstrated in the mid and 
apical lateral wall, basal and apical inferolateral wall of the left ventricle and the mid 
anteroseptum. The centre panel demonstrates midwall LGE in the mid inferoseptum of 
his 53 year old sister (patient 2) who also has BrS. The right sided panel demonstrates 
midwall LGE in the basal and mid septum and anteroseptum of an unrelated 40 year old 
man (patient 3) with BrS who was subsequently found to have a desmoplakin gene 
mutation, a Task Force criterion for arrhythmogenic right ventricular cardiomyopathy. 
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Figure 2 Electrocardiograms during diagnostic ajmaline testing in a 53 year old lady 
(patient 2) with Brugada syndrome (BrS). At peak ajmaline there is a characteristic type 
1 BrS pattern with coved ST elevation ≥0.2mV and T wave inversion in leads V23 (V2 in 
the 3rd intercostal space) and V22 (V2 in the 2nd intercostal space). 
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Figure 3 Resting electrocardiograms from a 53 year old lady (patient 2) with Brugada 
syndrome. Panel A demonstrates her presenting ECG with T wave inversion in leads V1 
and V2, a minor criterion for arrhythmogenic right ventricular cardiomyopathy (ARVC). 
Panel B demonstrates her ECG after two years of follow-up with T wave inversion 
throughout all precordial leads, a major Task Force criterion for ARVC. 
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Tables 
Table 1 Demographic and clinical characteristics of Brugada syndrome patients and 
healthy controls. 
 Brugada patients 
(n=78) 
Healthy controls 
(n=78) 
Age 44±15 42±14 
Sex (male; %) 64 64 
Syncope (%) 19 0 
Cardiac arrest (%) 9 0 
Spontaneous type 1 BrS ECG (%) 23 0 
SCN5A mutation presence (%) 26 NA 
Family history SCD <45 years (%) 49 0 
Abnormal SAECG (%) 33 0 
 
BrS, Brugada syndrome; ECG, electrocardiogram; SCN5A, gene encoding the cardiac 
sodium channel; SCD, sudden cardiac death; SAECG, signal averaged electrocardiogram; 
NA, not applicable 
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Table 2 Comparison of cardiovascular magnetic resonance findings in patients with 
Brugada syndrome and healthy controls. 
 Brugada patients 
(n=78) 
Healthy controls 
(n=78) 
p-value 
LA area (cm
2
/m
2
) 12±2 11±2 0.275 
LVEDV (mL/m
2
) 74±13 76±13 0.260 
LVESV (mL/m
2
) 26±7 27±6 0.139 
LVEF (%) 65±5 64±5 0.328 
LV mass (g/m
2
) 57±13 56±13 0.401 
RA area (cm
2
/m
2
) 11±2 11±2 0.423 
RVEDV (mL/m
2
) 78±16 76±13 0.622 
RVESV (mL/m
2
) 31±10 28±6 0.038 
RVEF (%) 61±8 64±5 0.004 
LGE presence (n) 6 (8%) 0 0.028 
 
LA, left atrium; RA, right atrium; LVEDV, left ventricular end diastolic volume; LVESV, left 
ventricular end systolic volume; LVEF, left ventricular ejection fraction; RVEDV, right 
ventricular end diastolic volume; RVESV, right ventricular end systolic volume; RVEF, 
right ventricular ejection fraction; LGE, late gadolinium enhancement 
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Table 3 Comparison of cardiovascular magnetic resonance findings in Brugada syndrome 
patients with and without SCN5A mutations. 
 Brugada with SCN5A 
mutation 
(n=20) 
Brugada without SCN5A 
mutation 
(n=34) 
p-value 
LA area (cm
2
/m
2
) 12±2 11±2 0.227 
LVEDV (mL/m
2
) 74±14 71±11 0.019 
LVESV (mL/m
2
) 27±6 24±6 0.024 
LVEF (%) 64±5 66±5 0.079 
LV mass (g/m2) 55±16 58±12 0.408 
RA area (cm
2
/m
2
) 12±2 10±2 0.010 
RVEDV (mL/m
2
) 78±18 74±12 0.038 
RVESV (mL/m
2
) 32±11 29±9 0.166 
RVEF (%) 59±10 61±7 0.387 
LGE presence (n) 0 3 n/a 
 
LA, left atrium; RA, right atrium; LVEDV, left ventricular end diastolic volume; LVESV, left 
ventricular end systolic volume; LVEF, left ventricular ejection fraction; RVEDV, right 
ventricular end diastolic volume; RVESV, right ventricular end systolic volume; RVEF, 
right ventricular ejection fraction; LGE, late gadolinium enhancement 
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Table 4 Patterns of late gadolinium enhancement in Brugada syndrome patients and 
their associated clinical characteristics. 
Patient Sex Age Symptoms Spont type 
1 ECG 
FHx SCD  SCN5A 
mutation 
LGE pattern 
1 M 45 None No Yes Untested Midwall 
Mid and apical lateral wall, basal 
and apical inferolateral wall, mid 
anteroseptum (figure 1) 
2 F 53 None No Yes No Midwall 
Mid inferoseptum (figure 1) 
3 M 40 None No Yes No Midwall 
Basal and mid 
septum/anteroseptum (figure 1) 
4 M 60 None Yes Yes No Midwall 
Basal inferolateral 
5 M 54 None No Yes Untested Basal inferior RV insertion point 
6 M 19 None No No Untested Basal anterior RV insertion point 
 
ECG, electrocardiogram; FHx SCD, family history of sudden cardiac death; SCN5A, gene 
encoding the cardiac sodium channel; LGE, late gadolinium enhancement 
 
 
